A new study published in The Lancet Oncology has found that estrogen plus progestin hormone therapy increases breast cancer risk in women under 55 with a uterus, while estrogen alone reduces the risk. The study suggests that timing and type of hormone therapy can significantly impact potential outcomes.
The research is based on two groups of participants: those who still have their uterus and those who do not. For women with a uterus, estrogen plus progestin is necessary due to the thickening of the uterine lining, which can lead to endometrial cancer. In contrast, estrogen alone can reduce breast cancer risk in women without a uterus.
The study’s findings come as no surprise, given previous research on hormone replacement therapy has shown similar results. However, this new study provides more insight into the impact of hormone therapy on young women, who are at higher risk for breast cancer due to their age.
Hormone replacement therapy can be beneficial in reducing menopausal symptoms and preventing certain cancers, but it also carries risks such as heart disease, stroke, and blood clots. It’s essential that women consult their doctor and consider their family history when deciding on hormone therapy. With the right guidance, hormone replacement therapy can be an effective treatment option for many perimenopausal symptoms.
Source: https://www.cbsnews.com/news/hormone-therapy-breast-cancer-risk-study